Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Stepanova

Showing results (91-100 of 242) with videos related to

Pageof 25
Sort By:
The American Journal of Managed Care|April 10, 2020
Outcomes of liver transplantation by insurance types in the United StatesMaria Stepanova, Saleh Al Qahtani, Alita Mishra, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2021
Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of LifeZobair M Younossi, Maria Stepanova, Rebecca A Taub, et al.
The Journal of Infectious Diseases|January 3, 2018
Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free RegimensMaria Stepanova, Alexander Thompson, Joseph Doyle, et al.
Journal of Hepatology|January 29, 2024
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver diseaseZobair M Younossi, James M Paik, Maria Stepanova, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 19, 2021
The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United StatesZobair M Younossi, Michael Harring, Youssef Younossi, et al.
Gut|August 2, 2019
Epidemiology of chronic liver diseases in the USA in the past three decadesZobair M Younossi, Maria Stepanova, Youssef Younossi, et al.
Hepatology Communications|February 27, 2026
Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosisZobair M Younossi, Fatema Nader, Dominic Labriola, et al.
Medicine|November 3, 2012
Nonalcoholic fatty liver disease in lean individuals in the United StatesZobair M Younossi, Maria Stepanova, Francesco Negro, et al.
Gastro Hep Advances|July 22, 2025
Assessments of Health Utilities in Patients With Metabolic Dysfunction-Associated Steatohepatitis: Cross-Walk Between Disease-Specific Chronic Liver Disease Questionnaire, Short Form SF-6D, and EuroQol EQ-5D InstrumentsZobair M Younossi, Maria Stepanova, Yestle Kim, et al.
Hepatology (Baltimore, Md.)|September 9, 2024
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosisZobair M Younossi, Maria Stepanova, Andrei Racila, et al.
Pageof 25

Showing results (91-100 of 242) with videos related to

Sort By:
Pageof 25
The American Journal of Managed Care|April 10, 2020
Outcomes of liver transplantation by insurance types in the United StatesMaria Stepanova, Saleh Al Qahtani, Alita Mishra, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 30, 2021
Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of LifeZobair M Younossi, Maria Stepanova, Rebecca A Taub, et al.
The Journal of Infectious Diseases|January 3, 2018
Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free RegimensMaria Stepanova, Alexander Thompson, Joseph Doyle, et al.
Journal of Hepatology|January 29, 2024
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver diseaseZobair M Younossi, James M Paik, Maria Stepanova, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 19, 2021
The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United StatesZobair M Younossi, Michael Harring, Youssef Younossi, et al.
Gut|August 2, 2019
Epidemiology of chronic liver diseases in the USA in the past three decadesZobair M Younossi, Maria Stepanova, Youssef Younossi, et al.
Hepatology Communications|February 27, 2026
Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosisZobair M Younossi, Fatema Nader, Dominic Labriola, et al.
Medicine|November 3, 2012
Nonalcoholic fatty liver disease in lean individuals in the United StatesZobair M Younossi, Maria Stepanova, Francesco Negro, et al.
Gastro Hep Advances|July 22, 2025
Assessments of Health Utilities in Patients With Metabolic Dysfunction-Associated Steatohepatitis: Cross-Walk Between Disease-Specific Chronic Liver Disease Questionnaire, Short Form SF-6D, and EuroQol EQ-5D InstrumentsZobair M Younossi, Maria Stepanova, Yestle Kim, et al.
Hepatology (Baltimore, Md.)|September 9, 2024
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosisZobair M Younossi, Maria Stepanova, Andrei Racila, et al.
Pageof 25